In this book, the authors present current research in the study of non-small cell lung cancer. Topics discussed include the preclinical and clinical advances of epigenetics in lung cancer; therapeutic antibodies and non-coding RNAs (ncRNAs) in non-small cell lung cancer; molecular profiling in lung cancer specimens leads to targeted therapeutic options in patients with non-small cell lung carcinoma; the role of radiation dose escalation in the treatment of stage III locally advanced inoperable non-small cell lung cancer; and mechanisms of resistance to EGFR inhibitors.
Table of Contents
Preface; Therapeutic Antibodies in Non-Small Cell Lung Cancer: An Overview & Future Directions; Non-Coding RNAs (ncRNAs) in Non-small Cell Lung Cancer (NSCLC); Epigenetics in Lung Cancer: Preclinical & Clinical Advances; Molecular Profiling in Lung Cancer Specimens Leads to Targeted Therapeutic Options in Patients with Non-Small Cell Lung Carcinoma (NSCLC); The Role of Radiation Dose Escalation in the Treatment of Stage III Locally Advanced Inoperable Non-Small Cell Lung Cancer: Where Are We Now?; Mechanisms of Resistance to EGFR Inhibitors; Index.